Stoke Therapeutics, Inc.
STOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | 0.06 | -0.00 | 0.24 |
| FCF Yield | -2.21% | -3.86% | 34.22% | -3.69% |
| EV / EBITDA | -30.03 | -20.97 | 1.01 | -38.35 |
| Quality | ||||
| ROIC | -13.09% | -7.79% | 29.98% | -5.78% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.79 | 1.08 | 1.17 | 2.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 181.20% | 182.73% | 135.82% | 43.37% |
| Free Cash Flow Growth | -19.24% | -119.42% | 666.71% | -6.98% |
| Safety | ||||
| Net Debt / EBITDA | 1.94 | 3.69 | -2.44 | 9.57 |
| Interest Coverage | -12.44 | -9,100.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 91.74 | -356.33 | -182.50 | -200.12 |